Alphabet, GeneScience, AstraZeneca, Shire, Novartis, Ping An, KPC and Stevanato are in line for exits after the drug delivery technology developer filed to go public.

The Boston Scientific-backed medical device maker has filed to raise up to $100m in an offering on the Nasdaq Global Market.

The GV-backed heart disease treatment developer intends to go public this year having secured $248m in venture funding.

Microsoft is reportedly paying over $500m for the MassMutual Ventures and National Grid Partners-backed cybersecurity software provider.

Dell-backed cybersecurity software producer Netskope has raised just over $1bn to date, having completed a $300m round led by Iconiq Growth.

SoftBank Vision Fund 2 and Intuit helped supply fresh funding for the equity-free capital provider to boost its expansion and broaden its product offering.

Block.one's blockchain technology spinoff is joining forces with publicly listed Far Peak Acquisition Corporation at a $9bn valauation.

GV participated in a series C round for the online flexible staffing portal at a valuation of $560m, hiking its overall funding to $100m.

Munich Re and Microsoft helped CO2-to-chemicals technology provider Twelve raise $57m while Eli Lilly and Kaiser Permanente-backed CRO dMed-Clinipac secured $50m.

The blockchain payment technology provider is set to undergo a $4.5bn reverse takeover having previously secured over $680m from investors including FTX, Baidu, Bitmain, CreditEase and Wanxiang.